Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:ESPR NASDAQ:KURA NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.31-2.4%$5.64$1.85▼$7.18$891.30M1.222.12 million shs2.18 million shsESPREsperion Therapeutics$3.13$2.56$0.76▼$4.18$805.76M0.9121.26 million shs6.70 million shsKURAKura Oncology$11.25+1.1%$9.01$5.45▼$12.49$988.06M0.321.66 million shs2.49 million shsNERVMinerva Neurosciences$5.26-0.8%$6.18$1.35▼$12.46$246.92M-0.08149,931 shs84,007 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.39%+1.92%-15.18%+8.37%+169.54%ESPREsperion Therapeutics0.00%+0.32%+58.88%-10.06%+266.94%KURAKura Oncology+1.08%+22.02%+18.05%+32.98%+81.45%NERVMinerva Neurosciences-0.75%+0.96%-28.44%-16.64%+262.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.31-2.4%$5.64$1.85▼$7.18$891.30M1.222.12 million shs2.18 million shsESPREsperion Therapeutics$3.13$2.56$0.76▼$4.18$805.76M0.9121.26 million shs6.70 million shsKURAKura Oncology$11.25+1.1%$9.01$5.45▼$12.49$988.06M0.321.66 million shs2.49 million shsNERVMinerva Neurosciences$5.26-0.8%$6.18$1.35▼$12.46$246.92M-0.08149,931 shs84,007 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.39%+1.92%-15.18%+8.37%+169.54%ESPREsperion Therapeutics0.00%+0.32%+58.88%-10.06%+266.94%KURAKura Oncology+1.08%+22.02%+18.05%+32.98%+81.45%NERVMinerva Neurosciences-0.75%+0.96%-28.44%-16.64%+262.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00201.32% UpsideESPREsperion Therapeutics 2.00Hold$5.5477.00% UpsideKURAKura Oncology 2.69Moderate Buy$26.38134.44% UpsideNERVMinerva Neurosciences 2.00Hold$10.5099.62% UpsideCurrent Analyst Ratings BreakdownLatest NERV, ESPR, ANNX, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.164/21/2026ESPREsperion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026KURAKura Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.25 per shareN/AESPREsperion Therapeutics$418.24M1.93N/AN/A($1.20) per share-2.61KURAKura Oncology$67.48M14.80N/AN/A$1.22 per share9.22NERVMinerva NeurosciencesN/AN/AN/AN/A($5.45) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%N/AESPREsperion Therapeutics-$22.68M-$0.06N/A14.232.540.12%-0.14%0.12%8/4/2026 (Estimated)KURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)NERVMinerva Neurosciences-$293.42M-$29.16N/A1.09N/AN/AN/A-32.63%N/ALatest NERV, ESPR, ANNX, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/8/2026Q1 2026ESPREsperion Therapeutics-$0.02-$0.10-$0.08-$0.10$84.52 million$80.10 million5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million3/5/2026Q4 2025KURAKura Oncology-$0.72-$0.92-$0.20-$0.92$34.71 million$17.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35ESPREsperion TherapeuticsN/A1.531.18KURAKura Oncology0.096.156.14NERVMinerva NeurosciencesN/A17.6517.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AESPREsperion Therapeutics47.39%KURAKura OncologyN/ANERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%ESPREsperion Therapeutics1.60%KURAKura Oncology7.60%NERVMinerva Neurosciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million144.40 millionOptionableESPREsperion Therapeutics200257.43 million253.31 millionOptionableKURAKura Oncology13088.77 million82.03 millionOptionableNERVMinerva Neurosciences946.59 million41.74 millionNot OptionableNERV, ESPR, ANNX, and KURA HeadlinesRecent News About These CompaniesAll You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to BuyMay 20 at 1:01 PM | zacks.comMinerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 20 at 10:35 AM | zacks.comMinerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average - Here's WhyMay 19, 2026 | americanbankingnews.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 18, 2026 | globenewswire.comMinerva Neurosciences (NASDAQ:NERV) Cut to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comMinerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | finanznachrichten.deMinerva Neurosciences (NASDAQ:NERV) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPSMay 5, 2026 | marketbeat.comMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | globenewswire.comMinerva Neurosciences, Inc (NASDAQ:NERV) Short Interest UpdateMay 1, 2026 | marketbeat.comMinerva Neurosciences (NERV) price target increased by 31.03% to 9.69April 28, 2026 | msn.comCitizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationApril 16, 2026 | msn.comMinerva launched with New Outperform at Citizens on schizophrenia candidateApril 15, 2026 | seekingalpha.comMinerva Neurosciences Sets 2026 Annual Shareholder Meeting TimelineApril 6, 2026 | tipranks.comMinerva Announces Leadership TransitionApril 2, 2026 | globenewswire.comMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMarch 31, 2026 | globenewswire.comMinerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of SchizophreniaMarch 31, 2026 | seekingalpha.comMinerva Neurosciences (NERV) price target increased by 61.11% to 7.40March 27, 2026 | msn.comMinerva Neurosciences, Inc: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | finanznachrichten.deMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | globenewswire.comMinerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumMarch 12, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMarch 11, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNERV, ESPR, ANNX, and KURA Company DescriptionsAnnexon NASDAQ:ANNX$5.31 -0.13 (-2.39%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.36 +0.05 (+0.96%) As of 05/22/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Esperion Therapeutics NASDAQ:ESPR$3.13 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.12 0.00 (-0.16%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Kura Oncology NASDAQ:KURA$11.25 +0.12 (+1.08%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$11.10 -0.15 (-1.29%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Minerva Neurosciences NASDAQ:NERV$5.26 -0.04 (-0.75%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.20 -0.06 (-1.24%) As of 05/22/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
